New drug combo takes on tough cancers in early trial
NCT ID NCT04896697
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tested a new drug called vilastobart, alone or with another drug (atezolizumab), in 125 people with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety and find the right dose. Researchers also looked for signs that the tumors shrank.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
vilastobart (XTX101) and atezolizumab
What this could lead to
If successful, this could point toward a new treatment option for advanced solid tumors that have not responded to standard therapies.
What could go wrong
This is a very early first-in-human trial, so safety and effectiveness are not yet proven. The small size and early phase mean results may not lead to a widely available treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
California Cancer Associates for Research and Excellence, cCARE
Encinitas, California, 92024, United States
-
California Cancer Associates for Research and Excellence, cCARE
San Marcos, California, 92069, United States
-
Carolina BioOncology Institute
Huntersville, North Carolina, 28078, United States
-
City of Hope
Duarte, California, 91010, United States
-
City of Hope-Lennar
Irvine, California, 92618, United States
-
City of Hope-Upland
Upland, California, 91786, United States
-
Duke University Medical Center
Durham, North Carolina, 27710, United States
-
Mary Crowley Cancer Research
Dallas, Texas, 75230, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
Mayo Clinic Hospital
Phoenix, Arizona, 85054, United States
-
Mayo Clinic Hospital
Jacksonville, Florida, 32224, United States
-
Mayo Clinic Hospital
Rochester, Minnesota, 55905, United States
-
NEXT Virginia
Fairfax, Virginia, 22031, United States
-
Next Oncology
Austin, Texas, 78758, United States
-
Sarah Cannon Research Institute at Florida Cancer Specialists
Orlando, Florida, 32827, United States
-
Tranquil Clinical Research
Webster, Texas, 77598, United States
-
UCLA Hematology/Oncology- Santa Monica
Santa Monica, California, 90404, United States
-
USC/Norris Comprehensive Cancer Center
Los Angeles, California, 90033, United States
-
University of Pittsburgh Medical Center- Hillman Cancer Center
Pittsburgh, Pennsylvania, 15232, United States